Laurus Labs Ltd

Laurus Labs Ltd

Laurus Labs Ltd has announced its participation in the Antique Pharma Investor Day on September 07, 2026, in Hyderabad. The meeting will be an in-person interaction, and no unpublished price-sensitive information will be shared.

Laurus Labs Ltd

Laurus Labs Ltd has announced an analyst/investor meet on August 19, 2026, as part of the 22nd Annual Global Investor Conference in Mumbai.

Laurus Labs Ltd

Laurus Labs Ltd has been assigned an ESG score of 63 out of 100 by NSE Sustainability Ratings and Analytics Limited for FY 2026.

Laurus Labs Ltd

Laurus Labs Ltd reported Q1 FY27 earnings, with revenue of INR2,026 crores, a 29% growth, driven by commercial supplies in CDMO segment and continued strength in affordable medicine portfolio. Gross margins were healthy at 62.7%, and EBITDA margins expanded to 31.8%. The company signed a development and commercial agreement with Aarvik Therapeutics for 2 ADC molecules for India markets, and onboarded a big pharma client with significant opportunities ahead.

Laurus Labs Ltd

Laurus Labs Ltd has allotted 62,635 equity shares to eligible employees on exercise of ESOPs, with a total paid-up capital of Rs.1,08,06,24,436/- divided into 54,03,12,218 equity shares of Rs.2/- each.

Laurus Labs Ltd

Laurus Labs Ltd has received an order from the Hon'ble National Company Law Tribunal, Amravati Special Branch, directing the company to serve a notice of hearing on the Composite Scheme of Arrangement. The next date of hearing is September 10, 2026.

Laurus Labs Ltd

Laurus Labs Ltd has published its unaudited financial results for the quarter ended June 30, 2026, in compliance with SEBI regulations.

Laurus Labs Ltd

Laurus Labs Ltd has announced the audio recording of its Q1 FY27 Results Conference Call, hosted on July 24, 2026, as per Regulations 30 & 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Laurus Labs Ltd

Laurus Labs Ltd has announced its Q1 FY27 results, with revenue at ₹ 2,026 Cr, a 29% growth from the same period last year, and EBITDA at ₹ 644 Cr, a 66% growth. The company has also reported strong growth in its CDMO business, driven by commercial projects, and steady momentum in its Affordable Medicines division.

Laurus Labs Ltd

Laurus Labs Ltd has announced its Q1 FY 2027 results, with revenue of ₹ 2,026 Cr, a 29% growth, and EBITDA of ₹ 644 Cr, with margins of 31.8%. The company has also highlighted its continued investment in manufacturing network expansion and niche capabilities.

Laurus Labs Ltd

Laurus Labs Ltd has announced the retirement of Dr. Rajesh Koshy Chandy as an Independent Director, effective July 26, 2026, after completing his second term.

Laurus Labs Ltd

Laurus Labs Ltd has announced its unaudited consolidated financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The results show a net profit of ₹361.99 crore, with earnings per equity share of ₹6.81.

Laurus Labs Ltd

Laurus Labs Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit after tax of ₹361.99 crore, a 124% increase from the same quarter last year. The company's revenue from operations was ₹2,026.31 crore, a 29% increase from the same quarter last year. The results were approved by the Board of Directors at their meeting held on July 24, 2026.